Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 11;14(3):194. doi: 10.1038/s41419-023-05699-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Pictures showed all the xenograft tumors formed by HCCLM3 cells in different groups. VEGFA-165 stands for recombinant human protein VEGFA-165. B The image closely up displays the tumors in situ, with yellow arrows indicating blood vessels forming on the tumor surface. C Growth curves drawn by tumor volume of xenograft tumors in the USP22 knockdown group and the control group at indicated time. D Tumor weight of xenografts in indicated groups were shown. E Protein levels of USP22, VEGFA and ZEB1 in every xenograft tumor were detected by western blotting. GAPDH was used as a control. F The protein expression of ZEB1 from (E) was quantified by densitometry, with GAPDH as the reference. P < 0.05 is considered statistically significant. G Pictures showed all the xenograft tumors formed by HCCLM3 cells in different groups. H Growth curves drawn by tumor volume of xenograft tumors in the USP22 overexpressing, USP22 overexpressing with ZEB1 deletion, and the control group at indicated time. I Tumor weight of xenografts in indicated groups were shown. J Protein levels of USP22, and ZEB1 in every xenograft tumor were detected by western blotting. GAPDH was used as a control.